Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

T. Teachey, David; R. Rheingold, Susan; L. Maude, Shannon; Zugmaier, Gerhard; M. Barrett, David; E. Seif, Alix; E. Nichols, Kim; Suppa, Erica; Kalos, Michael; A. Berg, Robert; C. Fitzgerald, Julie; Aplenc, Richard; Gore, Lia; A. Grupp, Stephan

doi:10.1182/blood-2013-02-485623

Public

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

Published in Blood • May 16, 2013

Authors:

David T. Teachey

Susan R. Rheingold

Shannon L. Maude

Abstract

Blinatumomab is a CD19/CD3-bispecific T-cell receptor-engaging (BiTE) antibody with efficacy in refractory B-precursor acute lymphoblastic leukemia. Some patients treated with blinatumomab and other T cell-activating therapies develop cytokine release syndrome (CRS). We hypothesized that patients wi...

Subject

Blinatumomab

Medicine

Macrophage activation syndrome

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!